Ceragon Networks Ltd. (NASDAQ:CRNT) represented a move of 1.42 percent or $-0.02 per share and closed its previous day trading session at $2.15. 545434 Shares were traded in the last trading session with an Average Volume of 572.89 Million Shares. The stock currently has a Market Capitalization of 169.12 Million.
Ceragon Networks Ltd. is a leading provider of high-capacity wireless backhaul solutions for cellular and fixed wireless operators, enterprises and government organizations. Ceragon’s modular FibeAir product family is recognized as the gold standard for backhaul transmission and is also one of the top solutions chosen by cellular operators for SONET/SDH rings. A scalable, future-proof solution for wireless transport of broadband services, FibeAir operates across multiple frequencies for IP and SONET/SDH protocols, supporting the emerging needs of next-generation networks that are evolving to all-IP based services, including triple-play. It leads the market in IP backhaul, offering a unique, native IP solution that provides the efficient, robust connectivity required for WiFi, WiMAX and converged networks.
The stock traded between $1.64 and $4.23 over 1-Year time period showing its price to sales ratio of 0.51. Ceragon Networks Ltd. (NASDAQ:CRNT).
Right now, the stock has a 50-Day Simple Moving Average of $4.57 and 200-Day Simple Moving Average of $-7.29. Its Price to Free Cash Flow is 563.73 and Price to Book of 1.32.
Analyst’s recommended the stock as 3 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Ceragon Networks Ltd. (NASDAQ:CRNT) reported its Actual EPS of $0.05/share. The analysts offering Earnings Estimates for the company were believing that Ceragon Networks Ltd. could bring EPS of $0.05/share. The difference between Actual EPS and Estimated EPS was 0 Percent. Thus showing an Earnings Surprise of 0 Percent.
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)
In the last trading session, Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) added its value by -1.79% closing at the price of $13.75. The stock currently has market capitalization of 399.99 Million, with average volume of 443.26 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is showing beta of 0.41. This particular value of beta suggests that Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has historically moved 41% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is at $-3.73.
The stock currently has RSI of 20.69. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States.
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) topped its 52-week high price of $29.00 on 08/31/17 and 52-Week Low Price of $13.45 on 02/06/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 4.90% and monthly volatility of 3.33% respectively.